scispace - formally typeset
P

Phil Riley

Researcher at Boston Children's Hospital

Publications -  23
Citations -  708

Phil Riley is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 15 publications receiving 436 citations. Previous affiliations of Phil Riley include Great Ormond Street Hospital.

Papers
More filters
Journal ArticleDOI

Disease activity, severity, and damage in the UK juvenile‐onset systemic lupus erythematosus cohort

L Watson, +19 more
- 01 Jul 2012 - 
TL;DR: The data on these patients from the UK JSLE Cohort Study indicate that severe organ involvement and significant disease activity are primary characteristics in children with juvenile SLE.
Journal ArticleDOI

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Obbina Abani, +7885 more
- 03 Mar 2022 - 
TL;DR: In patients hospitalised with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials.
Journal ArticleDOI

The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set.

Nicolino Ruperto, +29 more
- 01 Sep 2005 - 
TL;DR: The members of PRINTO propose a core set of criteria for the evaluation of response to therapy that is scientifically and clinically relevant and statistically validated and will help standardize the conduct and reporting of clinical trials and assist practitioners in deciding whether a patient with juvenile SLE has responded adequately to therapy.
Journal ArticleDOI

Presentation, Treatment Response and Short-Term Outcomes in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS)

Susanna Felsenstein, +19 more
- 14 Oct 2020 - 
TL;DR: Cases peaked approximately 4 weeks after the initial surge of COVID-19-like symptoms in the UK population, and immune modulating treatment was used in all patients, including intravenous immunoglobulin (IVIG), corticosteroids and cytokine blockers.
Journal ArticleDOI

Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups.

Joseph S Massias, +23 more
- 31 Mar 2020 - 
TL;DR: Adolescent JSLE patients diagnosed during adolescence exhibit greater disease activity and “classic” autoantibody, immune cell and complement patterns when compared with younger patients, which supports the hypothesis that pathomechanisms may vary between patient age groups.